NAVIGATING ANDA APPROVAL: A COMPREHENSIVE ANALYSIS OF SUBMISSION STRATEGIES AND POLICIES AND PROCEDURES FOR DEFICIENCY HANDLING
DOI:
https://doi.org/10.22159/ijpps.2026v18i5.57698Keywords:
Abbreviated new drug application, Generic drug regulatory approval, Refuse-to-receive, Submission quality and completeness, Chemistry, Manufacturing, Controls, Bioequivalence studies, FDA regulatory guidance, Deficiency management strategiesAbstract
Objective: This review provides a comprehensive understanding of regulatory expectations for generic drug approval in the United States. It highlights essential submission components, evaluation procedures, and common scientific and administrative issues that may lead to Refuse-to-Receive decisions. The review aims to guide applicants in improving submission quality and streamlining regulatory assessment.
Methods: Information was collected from official guidance documents, federal regulations, national generic drug program performance reports, and peer-reviewed literature related to regulatory science and generic drug development. Publications addressing filing requirements, laboratory and manufacturing standards, comparative clinical study principles, and deficiency management strategies were included, while outdated or irrelevant sources were excluded.
Results: This review summarizes the administrative, scientific, and technical requirements for complete generic drug submissions. It describes regulatory evaluation procedures, common deficiencies identified during review, and mechanisms for information requests. Although recent trends indicate improved submission quality and reduced approval timelines, gaps in scientific and technical documentation continue to limit first-cycle approvals.
Conclusion: Structured ANDA submissions supported by robust scientific evidence and early engagement with regulatory authorities can significantly reduce review delays and Refuse-to-Receive outcomes. Ensuring data completeness, adherence to regulatory guidelines, and systematic documentation from the early development stage improves the likelihood of timely approval for generic medicines.
Downloads
References
1. US Food and Drug Administration. Abbreviated new drug application (ANDA) [Internet]. Silver Spring (MD): FDA; 2023 [cited 2024 Feb 28]. Available from: https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda
2. Patel PM, Shah RR. Regulatory challenges in generic drug development and approval: a review. Int J Appl Pharm. 2019;11(6):1–7.
3. Code of Federal Regulations. Title 21, Part 314—Applications for FDA approval to market a new drug [Internet]. Washington (DC): US Government Publishing Office; [cited 2024 Feb 28]. Available from: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314
4. Bhaskar R, Ola M, Patil B. Regulatory requirement for pre- and post-approval management of generic drugs in the US. Int J Drug Regul Aff. 2023;11(2):94–109. Available from: https://www.ijdra.com/index.php/journal/article/view/611
5. Shah S, Badjatya JK. Preliminary requirements for ANDA filing. Int J Drug Regul Aff. 2018;6(4):1–8. Available from: https://www.ijdra.com/index.php/journal/article/view/276
6. Mahajan AP, Basarkar GD. Comparative overview of generic drug regulation in the US, Europe, Australia, and India. Int J Drug Regul Aff. 2025;13(1):40–48. Available from: https://www.ijdra.com/index.php/journal/article/view/747
7. US Food and Drug Administration. ANDA forms and submission requirements [Internet]. Silver Spring (MD): FDA; 2020 Dec 2 [cited 2024 Feb 28]. Available from: https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/abbreviated-new-drug-application-anda-forms-and-submission-requirements
8. US Food and Drug Administration. Filing an NDA and receiving an ANDA; 21 CFR 314.101 [Internet]. Ithaca (NY): Legal Information Institute; [cited 2024 Feb 28]. Available from: https://www.law.cornell.edu/cfr/text/21/314.101
9. US Food and Drug Administration. ANDA submissions—refuse-to-receive standards: guidance for industry [Internet]. Silver Spring (MD): FDA; 2016 [cited 2024 Feb 28]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/anda-submissions-refuse-receive-standards
10. US Food and Drug Administration. Generic drugs program activities report: fiscal year 2022 [Internet]. Silver Spring (MD): FDA; 2023 Feb 3 [cited 2024 Feb 28]. Available from: https://www.fda.gov/drugs/generic-drugs/generic-drugs-program-activities-report-fiscal-year-2022
11. US Food and Drug Administration. Generic drugs program activities report: fiscal year 2023 [Internet]. Silver Spring (MD): FDA; 2023 Dec 12 [cited 2024 Feb 28]. Available from: https://www.fda.gov/drugs/generic-drugs/generic-drugs-program-activities-report-fiscal-year-2023
12. Deshpande S, Patil S. Regulatory aspects and challenges in approval of generic pharmaceutical products. Asian J Pharm Clin Res. 2018;11(4):213–217.
13. Center for Drug Evaluation and Research. MAPP 5220.3: filing review deficiency communication procedures [Internet]. Silver Spring (MD): FDA; [cited 2024 Feb 28]. Available from: https://www.fda.gov/media/89070/download
14. US Food and Drug Administration. Generic drug application review process [Internet]. Silver Spring (MD): FDA; [cited 2024 Feb 28]. Available from: https://www.fda.gov/drugs/generic-drugs/generic-drug-application-review
Published
How to Cite
Issue
Section
Copyright (c) 2026 Pathipati Sunitha, S. Nagalakshmi, R. S. Sailesh, A. R. Aravind
This work is licensed under a Creative Commons Attribution 4.0 International License.